Cardiac hypertrophy and fibrosis are common comorbidities in CKD patients [32] and it is well-established that FGF23 directly promotes LVH via calcineurin/NFAT signaling activation in uremia [9,33]. This evidence concerns the gene FGF23 and uremia.